A Phase I Study of the Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in Patients With Malignant Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2018
At a glance
- Drugs LMB 100 (Primary) ; Paclitaxel
- Indications Mesothelioma
- Focus Adverse reactions
- 05 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 04 Apr 2018 Planned primary completion date changed from 1 Aug 2018 to 6 Aug 2019.